← Back to all trials
Not Yet Recruiting
NCT07662525
Atorvastatin Combined With NAC Plus Romiplostim for Management of ITP
Conditions: Immune Thrombocytopenic Purpura
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 50
Sponsor: Peking University People's Hospital
Location: Peking University People's Hospital Beijing
Summary
This is a prospective, single-arm, open-lable, single-center study and we aimed to determine whether atorvastatin combined with N-acetyl-L-cysteine (NAC) plus romiplostim could induce sustained response off-treatment (SRoT) in adult patients with ITP following CS failure.
Eligibility Criteria
Inclusion Criteria:
* Diagnosed with primary ITP;
* Aged ≥18 years;
* Patients with treatment failure or relapse after first-line corticosteriod therapy for ITP;
* Platelet count \ 2 times the upper limit of normal (ULN), ALT \> 2×ULN, or TBIL ≥ 1.5×ULN;
* eGFR \< 50 mL/min/1.73m²;
* Any other subjects deemed ineligible for enrollment by the investigator.
Source: ClinicalTrials.gov (NCT07662525). StuddyBuddy aggregates publicly available trial information.
